

PCL Department Publications - 1998

"A, B"

Scott BW, Wang S, **Burnham WM**, De Boni, U, Wojtowicz JM: Kindling-induced neurogenesis in the dentate gyrus of the rat. *Neurosci. Letts.* 248: 73-76 (1998).

Mingo NS, Cottrell GA, Mendonca A, Gombos Z, Eubanks JH, **Burnham WM**: Amygdala-kindled and electroconvulsive seizures alter hippocampal expression of the m1 and m3 muscarinic cholinergic receptor genes. *Brain Res.* 810: 9-15 (1998).

"C, D"

Kapur S, Zipursky R.B, Remington G, Jones C, **DaSilva JN**, Wilson AA, Houle S: 5-HT₂ and D₂ receptor occupancy of olanzapine in schizophrenia: a PET investigation. *Am J Psychiatry* 155: 921-928 (1998).

Wilson AA, Inaba T, Fisher N, Dixon L, Nobrega J, **DaSilva JN**, Houle S: Derivatives of WAY 100635 as potential imaging agents for 5-HT_{1A} receptors: syntheses, radiosyntheses, in vitro and in vivo evaluation. *Nucl Med Biol.* 25: 769-776 (1998).

Hussey H, **DaSilva JN**, Greenwald E, Cheung K, Kapur S, Wilson AA, Houle S: Statistical power analysis of in vivo studies in rat brain using PET radiotracers. In: Myers R, Cunningham B, Bailey D, Jones T, eds. *Quantification of Brain Function using PET*. Academic Press, Dan Diego, pp. 273-277 (1998).

Wilson AA, Inaba T, Fisher N, **DaSilva JN**, Houle S: A human liver model of metabolism as a tool in the identification of potential PET radiotracers. *Op cit.* pp. 279-283 (1998).

Dorian P, Newman D, Greene M: Implantable defibrillators and/or amiodarone: alternatives or complementary therapies. *Int J Clin Practice* 52: 425-428 (1998).

Kerr CR, Boone J, Connolly SJ, **Dorian P**, Green M, Klein G, Newman D, Sheldon R, Talajic M: The Canadian Registry of Atrial Fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation. *Am J Cardiology* 82: 82N-85N (1998).

Khaykin Y, **Dorian P**, Baker B, Shapiro C, Sandor P, Mironov D, Irvine J, Newman D: Autonomic correlates of antidepressant treatment using heart-rate variability analysis. *Canad J Psychiatry* 43: 183-186 (1998).

Nanthakumar K, **Dorian P**, Ham M, Lam P, Lau C, Nishimura S, Newman D: When pacemakers fail: an analysis of clinical presentation and risk in 120 patients with failed devices. *Pacing & Clin Electrophysiology* 21: 87-93 (1998).

Sandor P, Baker B, Irvine J, **Dorian P**, McKessok D, Mendlowitz S: Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients. *Depression & Anxiety* 7: 69-72 (1998).

"E, F"

Csizmadia F, and **Endrenyi L**: Model-independent estimation of lag-times with first-order absorption and disposition. *J Pharm Sci.* 87: 608-612 (1998).

Endrenyi L, and Midha KK: Individual bioequivalence - has its time come? *Eur J Pharm Sci.* 6: 271-277 (1998)

Endrenyi L, and Hao Y: Asymmetry of the mean-variability tradeoff raises questions about the model in investigations of individual bioequivalence. *Int J Clin Pharmacol Ther.* 36: 450-457 (1998).

Endrenyi L, Csizmadia F, Tothfalusi L, and Chen ML: Metrics comparing simulated early concentration profiles for the determination of bioequivalence. *Pharm Res.* 15: 1291-1298 (1998).

Endrenyi L, Amidon GL, Midha KK, and Skelly JP: Individual bioequivalence: attractive in principle, difficult in practice. *Pharm Res.* 15: 1321-1325 (1998).

Endrenyi L, Csizmadia F, Tothfalusi F, Balch AH, and Chen ML: The duration of measuring partial AUCs for the assessment of bioequivalence. *Pharm Res.* 15: 399-404 (1998).

Endrenyi L, Tothfalusi L, Hao Y, and Taback N: Effects of uncertainties of the estimated variances on the evaluation of individual bioequivalence. XIXth International Biometric Conference, Cape Town, South Africa. Invited papers, pp. 127-136 (1998).

Kalow W, Tang BK, and **Endrenyi L**: Hypothesis: Comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. *Pharmacogenetics* 8: 283-289 (1998).

Endrenyi L: Bioequivalence. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. Wiley, Chichester-New York, Vol. 1, pp. 368-372 (1998).

"G"

El-Ghundi M, **George SR**, Drago J, Fletcher P, Fan T, Liu C, Sibley D, Westphal H, and O'Dowd BF: Disruption of the D1 dopamine receptor gene expression attenuates alcohol-seeking behavior. *Eur J. Pharmacol.* 353: 149-158 (1998).

George SR, Lee S, Varghese G, Zeman P, Seeman P, Ng GYK and O'Dowd BF: A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization. *J Biological Chem.* 273: 30244-30249 (1998).

Jin H, Nip S, O'Dowd BF and **George SR**: Activity of the D1 dopamine receptor is not altered by a point mutation in the first intracellular loop. *Biochem et Biophysica Acta* 1402: 165-170 (1998).

Kolakowski LF, O'Neill OP, Howard AD, Sullivan KA, Feighner SD, Sawzdargo M, Nguyen T, Kargman S, Shiao L, Hreniuk HL, Tan CP, Evans J, Abramovitz A, Chateaufneuf A, Coulombe N, Ng G, Johnson MP, Broussard SR, Smith RG, **George SR** and O'Dowd BF: Molecular characterization and expression of cloned human GALR2 and GALR3 galanin receptors. *J Neurochemistry* 71: 2239-2251 (1998).

Marchese A, Nguyen T, Malik P, Xu S, Cheng R, Heng HHQ, **George SR**, Kolakowski LF and O'Dowd BF: Cloning genes encoding receptors related to chemoattractant receptors. *Genomics* 50: 281-286 (1998).

O'Dowd BF, Marchese A, Nguyen T, Lynch K, Heng HHQ, Cheng R, Kolakowski LF and **George SR**: Discovery of three novel G protein-coupled receptor genes. *Genomics* 47: 310-314 (1998).

Thompson M, Comings DE, **George SR** and O'Dowd BF: Mutation screening of the dopamine D1 receptor gene in Tourette's syndrome and alcohol dependent patients. *Am J Med Genetics* 81: 241-244 (1998).

Zawarynski P, Tallerico T, Seeman P, Lee SP, O'Dowd BF and **George SR**: Dopamine D2 receptor dimers in human and rat brain. *FEBS Letters* 441: 383-386 (1998).

McPherson JP, **Goldenberg GJ**: Induction of Apoptosis by Deregulated Expression of DNA Topoisomerase IIa. *Cancer Res.* 58: 4519-4524 (1998).

Moore MJ, **Goldenberg GJ**: Antineoplastic Drugs. In: Kalant H, Roschlau WHE, eds. *Principles of Medical Pharmacology*, 6th ed. Oxford University Press, New York, pp. 759-774, (1998).

Tannock, IF, **Goldenberg GJ**: Drug Resistance and Experimental Chemotherapy. In: Tannock IF, Hill RP, eds. *The Basic Science of Oncology*. 3rd ed. McGraw-Hill Inc. New York, pp. 392-415 (1998).

Grad HA, Miller PA, and Copp PE: The top-40 prescription drugs in Canada(1997). *Ontario Dentist* 75:21-24 (1998).

Gaedigk A, Lekas P, Berchuk M, **Grant DM**: Novel sulfotransferases cloned by RT-PCR: real proteins or PCR artifacts?. *Chem Biol Interactions* 109: 43-52 (1998).

Gaedigk A, Tyndale RF, Jurima-Romet M, Sellers EM, **Grant DM**, Leeder JS: NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. *Pharmacogenetics* 8: 305-13 (1998)

Hughes NC, Janezic SA, McQueen KL, Jewett MA, Castranio T, Bell DA, **Grant DM**: Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. *Pharmacogenetics* 8: 55-66 (1998).

Lin HJ, Probst-Hensch NM, Hughes NC, Sakamoto GT, Louie AD, Kau IH, Lin BK, Lee DB, Lin J, Frankl HD, Lee ER, Hardy S, **Grant DM**, Haile RW: Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. *Pharmacogenetics* 8: 269-81 (1998).

Grupp LA, Lau V, Harding S: The reduction in alcohol intake in rats by isoproterenol is attenuated by indomethacin but not enalapril: relationship to blood glucose levels. *Psychopharmacology* 138: 167-75 (1998).

"H"

Afsar A, **Haas DA**, Rossouw PE, and Wood RE: Radiographic localization of

mandibular anesthesia landmarks. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics* 86: 234-241 (1998).

Haas DA: Localized complications from local anesthesia. *J California Dental Assoc* 26: 677-681 (1998).

Haas DA, Epstein JB, and Eggert FM: Antimicrobial resistance: dentistry's role. *J Can Dental Assoc* 64: 496-502 (1998).

Gerlai R, Roder JC, and **Hampson DR:** Altered spatial learning and memory in mice lacking the mGluR4 subtype of metabotropic glutamate receptor. *Behavioral Neuroscience* 112: 525-532 (1998).

Hampson DR, and Manalo JL: Activation of the kainate and AMPA subtypes of glutamate receptors by the neurotoxin domoic acid. *Natural Toxins* 6: 1-6 (1998).

Li W, **Harper PA,** Tang BK, Okey AB: Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. *Biochem Pharmacol* 56: 599-612 (1998).

Pohjanvirta R, Wong JMY, Li W, **Harper PA,** Tuomisto J, Okey AB: Point mutation in intron sequence causes altered carboxyl-terminal structure in the aryl hydrocarbon receptor of the most 2,3,7,8-tetrachlorodibenzo-p-dioxin-resistant rat strain. *Mol Pharmacol* 54: 86-93 (1998).

Bellows CG, Ciaccia A, **Heersche JN:** Osteoprogenitor cells in cell populations derived from mouse and rat calvaria differ in their response to corticosterone, cortisol, and cortisone. *Bone* 23: 119-25 (1998).

Heersche JN, Bellows CG, Ishida Y: The decrease in bone mass associated with aging and menopause. *J Prosthetic Dentistry* 79: 14-6 (1998).

Ishida Y, **Heersche JN:** Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. *J Bone Mineral Res.* 13: 1822-6 (1998).

von Schroeder HP, **Heersche JN:** Retinoic acid responsiveness of cells and tissues in developing fetal limbs evaluated in a RAREhsplacZ transgenic mouse model. *J Orthop Res.* 16: 355-64 (1998).

"I, J"

Fayz S, **Inaba T**: Zidovudine azido-reductase in human liver microsomes: Activation by ethacrynic acid, dipyridamole and indomethacin and inhibition by human immunodeficiency virus protease inhibitors. *Antimicrob Agents Chemother.* 42: 1654-1658 (1998).

Hashizume T, Mise M, Terauchi Y, O L, Fujii T, Miyazaki H, **Inaba T**: N-Dealkylation and hydroxylation of ebastine by human liver cytochrome P450. *Drug Metab Dispos.* 26: 566-571 (1998).

Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, **Inaba T**, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. *Xenobiotica* 28: 1041-1047 (1998).

Shimoda K, Shibasaki M, **Inaba T**, Cheung SW, Someya T, Takahashi S: Carbonyl reduction of timiperone in human liver cytosol. *Pharmacol Toxicol.* 83: 164-168 (1998).

Wilson AA, **Inaba T**, Fischer NE, Dixon LM, Nobrega J, DaSilva JN, Houle S: Derivatives of WAY 1000635 as potential imaging agents for 5-HT_{1A} receptors: Synthesis, radiosynthesis, in vitro and in vivo evaluation. *Nuclear Med Biol.* 25: 769-776 (1998).

Wilson AA, **Inaba T**, Fischer NE, DaSilva JN, Houle S: A human liver model of metabolism as a tool in the identification of potential PET radiotracers. In: Myers R, Cunningham B, Bailey D, Jones T, eds. *Quantification of Brain Function using PET*. Academic Press, San Diego pp. 279-283 (1998).

Chattergoon D, Verjee Z, Anderson M, Johnson D, McGuigan M, Koren G, **Ito S**: Carbamazepine interference with tricyclic antidepressant assay. *J Toxicol Clin Tox.* 36: 109-113 (1998)

Ito S, Weitzman S, Klein J, Greenberg M, Lau R, Atanakovic G, Koren G: Cisplatin-organic ion interactions: lack of effects of lack of cisplatin-ranitidine kinetic interactions in children, and supporting evidence from an in vitro study using brush border membrane vesicles of dog renal cortex. *Life Sci.* 62: PL387-392 (1998).

Ito S, Gow R, Verjee Z, Freedom R, Giesbrecht E, Zalstein E, Koren G: Propafenone and its active metabolite in neonates and infants. *J Clin Pharmacol.* 38: 496-501 (1998).

Koren G, **Ito S**: Do silicone breast implants affect breastfeeding? *Can Fam Phys.* 44: 2641-2642 (1998).

Koren G, Pastuszak A, **Ito S**: Drug Therapy: Drugs in pregnancy. *New Engl J Med.* 338: 1128-1137 (1998).

Stiskal J, Dunn M, Shennan A, O'Brien K, Kelly E, Koppel R, Cox DW, **Ito S**, Chappel L, Rabinovich M: Alpha 1-proteinase inhibitor inhibitor therapy for the prevention of bronchopulmonary dysplasia in premature infants. *Pediatrics* 101:89-94 (1998).

Watson-MacDonnell J, **Ito S**: Breastfeeding anaphylaxis Case Study. *J Hum Lact.* 14: 243-244 (1998).

Woodland C, Blowey D, **Ito S**, Koren G: Hypothetical framework for enhanced renal tubular secretion in cystic fibrosis. *Medical Hypothesis* 51: 489-491 (1998).

Woodland C, **Ito S**, Koren G: A model for the prediction of digoxin-drug interactions at the renal tubular cell level. *Ther Drug Monit.* 20: 134-138 (1998).

Ito S: Transfer of Drugs and Other Chemicals into Human Breast Milk. In: Dershewitz RA ed. *Ambulatory Pediatric Care*. Lippincott-Raven. 3rd ed. P1036-1043 (1998).

"K"

Chiu J, **Kalant H**, Le DA: Vasopressin opposes locomotor stimulation by ethanol, cocaine and amphetamine in mice: *Eur J Pharmacol.* 355: 11-7 (1998).

Eckardt MJ, File SE, Gessa GL, Grant KA, Guerri C, Hoffman PL, **Kalant H**, Koob GF, Li TK, Tabakoff B: Effects of moderate alcohol consumption on the central nervous system. *Alcoholism Clin Exp Res.* 22: 998-1040 (1998).

Kalant H: Research on tolerance: what can we learn from history? *Alcoholism Clin Exp Res.* 22: 67-76 (1998).

Kalant H: Role of science in the formulation of social policy on drugs. *Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales.* 192: 905-15 (1998).

Khanna JM, **Kalant H**, Chau A, Shah G: Effect of NMDA antagonists on development of rapid tolerance to various barbiturates. *Alcohol.* 15: 9-18 (1998).

Khanna JM, **Kalant H**, Chau A, Shah G: Rapid tolerance and crosstolerance to motor impairment effects of benzodiazepines, barbiturates, and ethanol. *Pharmacol Biochem Behavior* 59: 511-9 (1998).

Kalow W, Tang BK, Endrenyi L: Hypothesis: comparison of intra-individual variations can substitute for twin studies in drug research. *Pharmacogenetics* 8: 283-289 (1998).

Masellis J, Meltzer HY, Lieberman JA, Sevy S, Basile V, Macciardi FM, Cola P, Howard A, Badri F, Nothen M, **Kalow W**, Kennedy JL: Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. *Neuropsychopharmacology* 19: 123-132 (1998).

Özdemir V, Naranjo CA, Sulman RW, Herrmann N, Sellers EM, Reed K, **Kalow W**: The extent and determinations of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. *J Clin Psychopharmacol.* 18: 56-61 (1998).

Özdemir V, Naranjo CA, Herrmann N, Shulman RW, Sellers EM, Reed K, **Kalow W**: Determinants of inter-individual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. *J Clin Psychopharmacol.* 18: 198-207 (1998).

Chang XB, **Kartner N**, Seibert FS, Aleksandrov AA, Kloser AW, Kiser GL, Riordan JR: Heterologous expression systems for study of cystic fibrosis transmembrane conductance regulator. *Methods in Enzymology* 292: 616-29 (1998).

Kartner N, Riordan JR: Characterization of polyclonal and monoclonal antibodies to cystic fibrosis transmembrane conductance regulator. *Methods in Enzymology* 292: 629-52 (1998).

Zhang F, Kartner N, Lukacs GL: Limited proteolysis as a probe for arrested conformational maturation of delta F508 CFTR. *Nature Structural Biology* 5: 180-3 (1998).

Khanna JM, Kalant H, Chau A and Shah G: Rapid tolerance and cross-tolerance to motor impairment effects of benzodiazepines, barbiturates and ethanol. *Pharmacol Biochem Behav.* 59: 511-519 (1998).

Kalant H, **Khanna JM**: The Alcohols. In: Kalant H and Roschlau WHE, eds. *Principles of Medical Pharmacology*, 6th ed. Oxford University Press, New York, pp 303-316 (1998).

Sellers EM, **Khanna JM**, and Romach MK: Anxiolytics and hypnotics. *Op cit.* pp 317-330 (1998).

Warsh JJ, **Khanna JM**: Antidepressants and mood stabilizing agents. *Op cit.* pp 345-361 (1998).

Bailey B, Morris P, McMartin KI, Klein J, Duhart HM, Gillam MP, Binienda Z, Slikker W, Paule MG, **Koren G**: Transplacental pharmacokinetics of cocaine and benzoylecgonine in plasma and hair of rhesus monkeys. *Reproductive Toxicology* 12: 517-23 (1998).

Berkovitch M, Bistrizter T, Aladjem M, Burtin P, Dagan T, Chen-Levi Z, Freedom R, **Koren G**: Clinical relevance of therapeutic drug monitoring of digoxin and gentamicin in the saliva of children. *Ther Drug Monit.* 20: 253-6 (1998).

Carcao MD, Lau RC, Gupta A, Huerter H, **Koren G**, King SM: Sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocompromised children. *Pediatric Infect Dis J.* 17: 626-31 (1998).

Chattergoon DS, Verjee Z, Anderson M, Johnson D, McGuigan MA, **Koren G**, Ito S: Carbamazepine interference with an immune assay for tricyclic antidepressants in plasma. *J Toxicol Clin Toxicol.* 36: 109-13 (1998).

Diav-Citrin O, Park YH, Veerasuntharam G, Polachek H, Bologna M, Pastuszak A, **Koren G**: The safety of mesalamine in human pregnancy: a prospective controlled cohort study. *Gastroenterology* 114: 23-8 (1998).

Dolovich LR, Addis A, Vaillancourt JM, Power JD, **Koren G**, Einarson TR: Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. *BMJ.* 317: 839-43 (1998).

Einarson A, Phillips E, Mawji F, D'Alimonte D, Schick B, Addis A, Mastroiacova P, Mazzone T, Matsui D, **Koren G**: A prospective controlled multicentre study of clarithromycin in pregnancy. *Am J Perinatology* 15: 523-5 (1998).

Einarson A, **Koren G**: Counseling psychiatric patients about drug exposures during pregnancy. *Can Family Physician* 44: 981-3 (1998).

Einarson A, **Koren G**, Bergman U: Nausea and vomiting in pregnancy: a comparative European study. *Eur J Obstetr Gynecol Reprod Biol* 76: 1-3 (1998).

Fernandes O, Sabharwal M, Smiley T, Pastuszak A, **Koren G**, Einarson T: Moderate to heavy caffeine consumption during pregnancy and relationship to spontaneous abortion and abnormal fetal growth: a meta-analysis. *Reproductive Toxicology* 12: 435-44 (1998).

Gupta AK, **Koren G**, Shear NH: A double-blind, randomized, placebo-controlled trial of eutectic lidocaine/prilocaine cream 5% (EMLA) for analgesia prior to cryotherapy of warts in children and adults. *Ped Dermatol* 15: 129-33 (1998).

Inocencion G, Loebstein R, Lalkin A, Geist R, Petric M, **Koren G**: Managing exposure to chickenpox during pregnancy. New program. *Can Family Physician* 44: 745-7 (1998).

Ito S, Gow R, Verjee Z, Giesbrecht E, Dodo H, Freedom R, Tonn GR, Axelson JE, Zalstein E, Rosenberg HC, **Koren G**: Intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response. *J Clin Pharmacol* 38: 496-501 (1998).

Ito S, Weitzman S, Klein J, Greenberg M, Lau R, Atanakovic G, **Koren G**: Lack of cisplatin-ranitidine kinetic interactions: in vivo study in children, and in vitro study using dog renal brush border membrane vesicles. *Life Sci.* 62: 387-392 (1998).

Kennedy D, **Koren G**: Valproic acid use in psychiatry: issues in treating women of reproductive age. *J Psychiatry Neurosci.* 23: 223-8 (1998).

Khattak S, Rogan JW, Saunders EF, Theis JG, Arbus GS, **Koren G**: Efficacy of amlodipine in pediatric bone marrow transplant patients. *Clin Pediatrics* 37: 31-5 (1998).

Knight JM, Eliopoulos C, Klein J, Greenwald M, **Koren G**: Pharmacokinetic predisposition to nicotine from environmental tobacco smoke: a risk factor for pediatric asthma. *J Asthma* 35: 113-7 (1998).

Koren G, Nulman I, Addis A: Outcome of children exposed in utero to fluoxetine: a critical review. *Depression & Anxiety* 8 (Suppl 1): 27-31 (1998).

Koren G, Klein J, McMartin K: Diagnosing intrauterine exposure to cocaine by hair testing: six years of clinical use. *Therap Drug Monit* 20: 478-80 (1998)

Koren G, Ito S: Do silicone breast implants affect breastfeeding? *Can Family Physician* 44: 2641-2 (1998).

Koren G, Nulman I, Rovet J, Greenbaum R, Loebstein M, Einarson T: Long-term neurodevelopmental risks in children exposed in utero to cocaine. The Toronto Adoption Study. *Ann New York Acad Sci.* 846: 306-13 (1998).

Koren G, Woodland C, Ito S: Toxic digoxin-drug interactions: the major role of renal P-glycoprotein. *Veterinary Human Toxicol.* 40: 45-6 (1998).

Koren G, Pastuszak A, Ito S: Drugs in pregnancy. *New Engl J Med.* 338: 1128-37 (1998).

Koren G, Loebstein R, Nulman I: Fetal alcohol syndrome. Role of the family physician. *Can Family Physician* 44: 38-40 (1998).

Kulin NA, Pastuszak A, **Koren G**: Are the new SSRIs safe for pregnant women? *Can Family Physician* 44: 2081-3 (1998).

Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-Schechman AK, Cook L, Brochu J, Rieder M, **Koren G**: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. *JAMA* 279: 609-10 (1998).

Lalkin A, Loebstein R, Addis A, **Koren G**: Therapeutic approach to hypertension during pregnancy. *Can Family Physician* 44: 1245-7 (1998).

Lalkin A, Loebstein R, Addis A, Ramezani-Namin F, Mastroiacovo P, Mazzone T, Vial T, Bonati M, **Koren G**: The safety of omeprazole during pregnancy: a multicenter prospective controlled study. *Am J Obstetr Gynecol.* 179: 727-30 (1998).

Lau RC, Matsui D, Greenberg M, **Koren G**: Electronic measurement of compliance with mercaptopurine in pediatric patients with acute lymphoblastic leukemia. *Med Pediatric Oncology* 30: 85-90 (1998).

Lishner M, **Koren G**: Breast cancer during pregnancy. Approach to rational management. *Can Family Physician* 44: 265-6 (1998).

Loebstein R, **Koren G**: Clinical pharmacology and therapeutic drug monitoring in neonates and children. *Pediatrics in Review* 19: 423-8 (1998).

Loebstein R, **Koren G**: Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. *Pediatrics* 101: E8 (1998).

Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld AE, Schick B, Bonati M, Moretti M, Lalkin A, Pastuszak A, **Koren G**: Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. *Antimicrob Agents Chemoth.* 42: 1336-9 (1998).

London B, Jeron A, Zhou J, Buckett P, Han X, Mitchell GF, **Koren G**, Long QT: Ventricular arrhythmias in transgenic mice expressing the N terminus and first transmembrane segment of a voltage-gated potassium channel. *Proc Nat Acad Sci USA* 95: 2926-31 (1998).

Mazzotta P, Gupta A, Maltepe C, **Koren G**, Magee L: Pharmacologic treatment of nausea and vomiting during pregnancy. *Can Family Physician* 44: 1455-7 (1998).

- McMartin KI, Chu M, Kopecky E, Einarson TR, **Koren G**: Pregnancy outcome following maternal organic solvent exposure: a meta-analysis of epidemiologic studies. *Am J Ind Medicine* 34: 288-92 (1998).
- Mitchell GF, Jeron A, **Koren G**: Measurement of heart rate and Q-T interval in the conscious mouse. *Am J Physiol.* 274: H747-51 (1998).
- Moienafshari R, Bar-Oz B, Ford-Jones L, **Koren G**: How long should someone wait after CMV infection to start pregnancy? *Can Family Physician* 44: 2381-2 (1998).
- Nulman I, Berkovitch M, Klein J, Pastuszak A, Lester RS, Shear N, **Koren G**: Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety. *J Clin Pharmacol* 38: 926-30 (1998).
- Ondrusek N, Abramovitch R, Pencharz P, **Koren G**: Empirical examination of the ability of children to consent to clinical research. *J Med Ethics* 24: 158-65 (1998).
- Pastrakuljic A, Schwartz R, Simone C, Derewlany LO, Knie B, **Koren G**: Transplacental transfer and biotransformation studies of nicotine in the human placental cotyledon perfused in vitro. *Life Sci.* 63: 2333-42 (1998).
- Pastuszak AL, Schuler L, Speck-Martins CE, Coelho KE, Cordello SM, Vargas F, Brunoni D, Schwarz IV, Larrandaburu M, Safattle H, Meloni VF, **Koren G**: Use of misoprostol during pregnancy and Mobius' syndrome in infants. *New Eng J Med.* 338: 1881-5 (1998).
- Polygenis D, Wharton S, Malmberg C, Sherman N, Kennedy D, **Koren G**, Einarson TR: Moderate alcohol consumption during pregnancy and the incidence of fetal malformations: a meta-analysis. *Neurotox Teratol.* 20: 61-7 (1998).
- Rowe C, Koren T, **Koren G**: Errors by paediatric residents in calculating drug doses. *Arch Dis Childhood* 79: 56-8 (1998).
- Scalera A, **Koren G**: Rationale for treating pregnant smokers with nicotine patches. *Can Family Physician* 44: 1601-3 (1998).
- Shapiro L, Pastuszak A, Curto G **Koren G**: Is topical tretinoin safe during the first trimester? *Can Family Physician* 44: 495-8 (1998).
- Shuhaiber S, Pastuszak A, Schick B, Matsui D, Spivey G, Brochu J, **Koren G**: Pregnancy outcome following first trimester exposure to sumatriptan. *Neurology* 51: 581-3 (1998).
- Stevens B, **Koren G**: Evidence-based pain management for infants. *Current Opinion in Pediatrics* 10: 203-7 (1998).

Taddio A, Ohlsson A, Einarson TR, Stevens B, **Koren G**: A systematic review of lidocaine-prilocaine cream (EMLA) in the treatment of acute pain in neonates. *Pediatrics* 101: E1 (1998).

Theis JG, Chan HS, Greenberg ML, Malkin D, Karaskov V, Moncica I, **Koren G**, Doyle J: Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin. *Int J Clin Pharmacol Ther* 36: 61-4 (1998).

Thuma PE, Olivieri NF, Mabeza GF, Biemba G, Parry D, Zulu S, Fassos FF, McClelland RA, **Koren G**, Brittenham GM, Gordeuk VR: Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans. *Am J Tropical Med Hygiene* 58: 358-64 (1998).

Woodland C, Ito S, **Koren G**: A model for the prediction of digoxin-drug interactions at the renal tubular cell level. *Ther Drug Monit.* 20: 134-8 (1998)

Zhou J, Jeron A, London B, Han X, **Koren G**: Characterization of a slowly inactivating outward current in adult mouse ventricular myocytes. *Circulation Res* 83: 806-14 (1998).

"L"

Lanca AJ, De Cabo C: Arifuzzaman AI. Vaccarino FJ. Cholecystokinergic innervation of nucleus accumbens subregions. *Peptides* 19: 859-68 (1998).

Chiu J, Kalant H, and **Le AD**: Vasopressin opposes locomotor stimulation by ethanol, cocaine and amphetamine in mice. *Eur J Pharmacol.* 355: 11-17 (1998).

Le AD, Quan B, Juzysch W, Fletcher PJ, Shaham Y: Reinstatement of alcohol-seeking by priming injections of alcohol and exposure to stress in rats. *Psychopharmacology* 135: 169-174 (1998).

Poulos CX, Parker JL, and **Le AD**: Increased impulsivity after injected alcohol predicts later alcohol consumption in rats: evidence for "loss-of-control" drinking" and marked individual differences. *Behav Neurosci.* 112: 1247-1257 (1998).

Kofman O, **Li PP**, Warsh JJ: Lithium, but not carbamazepine, potentiates hyperactivity induced by intra-accumbens cholera toxin. *Pharmacol Biochem Behavior* 59: 191-200 (1998).

"M"

Lu W-Y, Xiong Z-Y, Orser BA, and **MacDonald JF**: Multiple sites of action of neomycin, Mg^{2+} and spermine on the NMDA receptors of rat hippocampal CA1 pyramidal neurones. *J Physiol. (Lond)*. 512 (Pt 1): 29-46 (1998).

MacDonald JF, Xiong XG, Lu WY, Raouf R, and Orser BA: Modulation of NMDA receptors. In: The glutamate synapse as a therapeutical target: Molecular organization and pathology of the glutamate synapse. Editors: Ole P. Ottersen, Iver A. Langmoen, Leif Gjerstad. *Progress In Brain Research* 116: 191-208 (1998).

McAdam LC, **MacDonald JF**, and Orser BA: Isobolographic analysis of the interactions between midazolam and propofol at GABA_A receptors in embryonic mouse neurons. *Anesthesiology* 89: 1444-54 (1998).

Orser BA, McAdam LC, Roder S and **MacDonald JF**: General anesthetics and their effects on GABA_A receptor desensitization. *Tox Lett*. 100-101: 217-224 (1998).

Xiong ZG, Raouf R, Lu WY, Wang LY, Orser BA, Dudek EM, Browning MD, **MacDonald JF**: Regulation of N-methyl-D-aspartate receptor function by constitutively active protein kinase C. *Mol Pharmacol*. 54:1055-63 (1998).

Colantonio CM, Kwan W-K, Czerwinski W, **Mitchell J**, Schimmer BP: Altered G protein activity in a desensitization-resistant mutant of the Y1 adrenocortical tumor cell line. *Endocrinology* 139: 626-633 (1998).

Mitchell J, Mayeenuddin LH: Purification, G protein activation, and partial amino acid sequence of a novel phospholipase C from squid photoreceptors. *Biochemistry* 37: 9064-9072 (1998).

Einarson TR, Iskedjian M, **Mittmann N**, Addis A: Meta-analysis of venlafaxine, SSRIs and TCAs in the treatment of major depressive disorder. *Can J Clin Pharmacol*. 5: 205-216 (1998).

Lanctot KL, Best TS, **Mittmann N**, Liu BA, Oh PI, Einarson TR, Naranjo CA: Efficacy and safety of neuroleptics in behavioural disorders associated with dementia. *J Clin Psychiatry* 59: 550-561 (1998).

Liu BA, Anderson G, **Mittmann N**, To T, Axell T, Shear NH: Use of selective serotonin reuptake inhibitors or tricyclic antidepressants and the risk of hip fracture in the elderly. *Lancet* 351: 1303-1307 (1998).

Mittmann N, Herrmann N, Shulman KI, Silver IL, Shear NH, Naranjo CA: Comparison of the Global Assessment of Functioning Scale and the Montgomery Asberg Depression Rating Scale in elderly depressed patients [letter]. *Int J Geriatric Psychiatry* 13: 568-574 (1998).

Mittmann N, Trakas K, Iskedjian M, Bradley CA, Einarson TR: A proposal for structured abstracts for health economic studies. *Annals Pharmacother*. 32: 1244-1246 (1998).

Mittmann N, Trakas K, Risebrough N, Liu BA: Utility scores for chronic conditions in a community-dwelling population. *PharmacoEconomics* 15: 369-376 (1998).

Bjarnason GA, Cripps C, Goel R, Fine S, Oza AM, Skillings JR, Kerr I, Germond CJ, **Moore MJ**, Maroun JA, Franssen E, Dulude H: Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer. *Am J Clin Oncology* 21: 537-42 (1998).

Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, Willan AR, Ernst S, **Moore MJ**, Neville A, Tannock IF: Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. *J Clin Oncology* 16: 2272-9 (1998).

Czaykowski PM, **Moore MJ**, Tannock IF: High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. *J Urology* 160: 2021-4 (1998).

Michael M, Tannock IF, Czaykowski PM, **Moore MJ**: Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience. *Br J Urology* 82: 366-372 (1998).

Michael M, **Moore MJ**: Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer. *Oncology* 12: 121-8 (1998).

Moore MJ, Feld R, Hedley D, Oza A, Siu LL: A phase II study of temozolomide in advanced untreated pancreatic cancer. *Investigational New Drugs* 16: 77-9 (1998).

Siu LL, Banerjee D, Khurana RJ, Pan X, Pflueger R, Tannock IF, **Moore MJ**: The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. *Clin Cancer Res*. 4: 559-65 (1998).

Siu LL, **Moore MJ**: Use of mesna to prevent ifosfamide-induced urotoxicity. *Supportive Care in Cancer* 6: 144-54 (1998).

"N"

Busto UE, **Naranjo CA**, Bremner KE, Peachey JE, Bologna M: Safety of ipsapirone treatment compared to lorazepam: Discontinuation effects. *J Psychiatry Neurosci.* 23: 35-44 (1998).

Busto UE, Pain T, Lanctot KL, Einarson TR, **Naranjo CA**: Assessment of the risk of therapeutic dose benzodiazepine withdrawal reactions using meta-analysis. *Can J Clin Pharmacol* 5: 161-168 (1998).

Lanctot KL, Best TS, Mittmann N, Liu BA, Oh PI, Einarson TR, **Naranjo CA**: Efficacy and safety of neuroleptics in behavioural disorders associated with dementia. *J Clin Psychiatry* 59: 550-561 (1998).

Naranjo CA: "Clinical Pharmacology in the 90's: A personal perspective on clinical psychopharmacology". *Can J Clin Pharmacol.* 5: 77-78 (1998).

Naranjo CA, Best T: Advances in the pharmacotherapy of cognitive deficits and behavioural disorders in dementia. *Can J Clin Pharmacol* 5: 98-109 (1998).

Ozdemir VO, **Naranjo CA**, Shulman RW, Herrmann N, Sellers EM, Reed K, Kalow W: Determinants of inter-individual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. *J Clin Psychopharmacol.* 18: 198-207 (1998).

Ozdemir VO, **Naranjo CA**, Herrmann N, Shulman RW, Sellers EM, Reed K, Kalow W: The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. *J Clin Psychopharmacol.* 18: 55-61 (1998).

Schaffer A, **Naranjo CA**: Recommended drug treatment strategies for the alcoholic patient. *Drugs* 56: 571-585 (1998).

Naranjo CA: Drug withdrawal syndromes. In: Gray J, ed. *Therapeutic Choices*, 2nd edition. Canadian Pharmacists Association, Ottawa, Canada, pp. 64-74 (1998).

Neuman MG: Cytokines and Inflamed Liver. *Clin Invest Med.* 23: 1-6 (1998).

Neuman MG, Shear NH, Bellentani S and Tiribelli C: Role of cytokines in ethanol-induced hepatocytotoxicity in Hep G2 cells. *Gastroenterology* 7: 157-169 (1998).

Braker E, Perlman MA, Adkins EM, Houlihan WJ, **Niznik HB** and Blakely RD: Antagonist binding sites on the serotonin transporter revealed by species scanning mutagenesis: An aromatic residue in transmembrane domain I mediates species specific recognition of mazindol and citalopram between human and *Drosophila* transporters. *J Biol Chem.* 273: 19459-19468 (1998).

Cardinaud B, Gilbert JM, Liu F, Sugamori KS, Vincent JD, **Niznik HB**, and Vernier P: Evolution and origin of the diversity of dopamine receptors in vertebrates. *Adv in Pharmacol.* 42: 936- 940 (1998).

Niznik HB, Liu F, Sugamori KS, Cardinaud B, and Vernier P: Expansion Of The Dopamine D1 Receptor Gene Family: Defining molecular, pharmacological and functional criteria for D1A, D1B, D1C and D1D receptors. *Adv in Pharmacol.* 42: 404-408 (1998).

Pristupa ZB, McConkey F, Liu F, Man HY, Lee FJ, Wang YT, and **Niznik HB**: Rapid bi-directional translocation of the dopamine transporter and the regulation of dopamine transport. *Synapse* 30: 79-87 (1998).

Sugamori KS, Scheideler MA, Vernier P, and **Niznik HB**: Dopamine D1B receptor chimeras reveal modulation of partial agonist activity by carboxyl terminal tail sequences. *J Neurochem.* 71:2593-2599 (1998).

Sugamori KS, Hamadanizedeh S, Scheideler MA, Hohlweg R, Vernier P, and **Niznik HB**: Functional differentiation of multiple dopamine D1like receptors by NNC-01-0012. *J Neurochem.* 71: 1685-1693 (1998).

Campioni EG, **Nobrega JN** and Sefton MV: HEMA/MMA microcapsule implants in rat brain: Biocompatibility assessment using [3H]PK11195 as a marker for gliosis. *Biometaterials* 19: 829-837 (1998).

D'Almeida V, Lobo LL, Hipolide DC, de Oliveira AC, **Nobrega JN** and Tufik S: Sleep deprivation induces brain region-specific decreases in glutathione levels. *NeuroReport* 9: 2853-2856 (1998).

Hipolide DC, Raymond R, Tufik S and **Nobrega JN**: Heterogeneous effects of REM sleep deprivation on binding to alpha and beta adrenergic receptor subtypes in rat brain. *Neuroscience* 86: 977-987 (1998).

Nobrega JN, Richter A, Jiwa D, Raymond R and Loscher W: Regional alterations in neuronal activity in dystonic hamster brain determined by quantitative cytochrome oxidase histochemistry. *Neuroscience* 83: 1215-1224 (1998).

Richter A, Ebert U, **Nobrega JN**, Vallbacka J, Fedrowitz M. and Loscher W: Immunohistochemical and neurochemical studies on nigral and striatal functions in the circling (ci) rat, a genetic animal model with spontaneous rotational behavior. *Neuroscience* 89: 461-471 (1998).

Sasaki T, Kennedy J and **Nobrega JN**: Regional brain changes in dopamine D1 receptors after long-term neuroleptic treatment: lack of correspondence with the development of vacuous chewing movements. *Behavioural Brain Research* 90: 125-132 (1998).

Wilson AA, Inaba T, Fischer N, Dixon LM, **Nobrega JN**, DaSilva J and Houle S: Derivatives of WAY 100635 as potential imaging agents for 5-HT1A receptors: Syntheses, radiosyntheses, and in vitro and in vivo evaluation. *Nuclear Med Biol* 25: 776-779 (1998).

Burnham WM, Gombos Z, **Nobrega JN** and Cottrell GA: Kindling-like effects of electroconvulsive shock seizures. In: Corcoran ME and Moshe SL, eds. *Kindling 5, Advances in Behavioral Biology*, v. 48,., Plenum Press, NY, 1998, pp.121-129.

"O"

Huang J, Niknahad H, Khan S, **O'Brien PJ**: Hepatocyte-catalysed detoxification of cyanide by L- and D-cysteine. *Biochem Pharmacol.* 55: 1983-1990 (1998).

Huang J, Khan S, **O'Brien PJ**: The glutathione dependence of inorganic sulfate formation from L- or D-cysteine in isolated rat hepatocytes. *Chem Biol Interactions* 110: 189-202 (1998).

Zhao ZS, Khan S, **O'Brien PJ**: Catecholic iron complexes as cytoprotective superoxide scavengers against hypoxia:reoxygenation injury in isolated hepatocytes. *Biochem Pharmacol.* 56: 825-30 (1998).

El-Ghundi M, George SR, Drago J, Fletcher P, Fan T, Liu C, Sibley D, Westphal H, and **O'Dowd BF**: Disruption of the D1 dopamine receptor gene expression attenuates alcohol-seeking behavior. *Eur J Pharmacol.* 353: 149-158 (1998).

George SR, Lee S, Varghese G, Zeman P, Seeman P, Ng GYK, and **O'Dowd BF**: A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization. *J Biol Chem.* 273: 30244-30249 (1998).

Jin H, Nip S, **O'Dowd BF**, and George SR: Activity of the D1 dopamine receptor is not altered by a point mutation in the first intracellular loop. *Biochem et Biophysica Acta* 1402: 165-170 (1998).

Kolakowski LF, O'Neill OP, Howard AD, Sullivan KA, Feighner SD, Sawzdargo M, Nguyen T, Kargman S, Shiao L, Hreniuk HL, Tan CP, Evans J, Abramovitz A, Chateaufneuf A, Coulombe N, Ng G, Johnson MP, Broussard SR, Smith RG, George SR and **O'Dowd BF**: Molecular characterization and expression of cloned human GALR2 and GALR3 galanin receptors. *J Neurochemistry* 71: 2239-2251 (1998).

Marchese A, Nguyen T, Malik P, Xu S, Cheng R, Heng HHQ, George SR, Kolakowski LF and **O'Dowd BF**: Cloning genes encoding receptors related to chemoattractant receptors. *Genomics* 50: 281-286 (1998).

O'Dowd BF, Marchese A, Nguyen T, Lynch K, Heng HHQ, Cheng R, Kolakowski LF and George SR: Discovery of three novel G protein-coupled receptor genes. *Genomics* 47: 310-314 (1998).

Thompson M, Comings DE, George SR and **O'Dowd BF**: Mutation screening of the dopamine D1 receptor gene in Tourette's syndrome and alcohol dependent patients. *Am J Med Genetics* 81: 241-244 (1998).

Zawarynski P, Talerico T, Seeman P, Lee SP, **O'Dowd BF** and George SR: Dopamine D2 receptor dimers in human and rat brain. *FEBS Letters* 441: 383-386 (1998).

Baker B, O'Kelly B, Szala JP, Katic M, McKessock D, **Ogilvie RI**, Basinski A, Tobe SW: Determinants of left ventricular mass in early hypertension. *Amer J Hypertension* 11: 1248-1251 (1998).

Ogilvie RI: Isolated systolic hypertension in the elderly- what's next? *Geriatric Nephrology and Urology* 8: 3-5 (1998).

Ogilvie RI, Zborowska-Sluis D: Captopril and angiotensin II (AT₁) receptor antagonist therapy in a pacing model of heart failure. *Can J Cardiol.* 14: 1025-1033 (1998).

Giannone JV, Li W, Probst M, **Okey AB**: Prolonged depletion of AH receptor without alteration of receptor mRNA levels after treatment of cells in culture with 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Biochem Pharmacol.* 55: 489-497 (1998).

Li, W. Harper PA, Tang BK, **Okey AB**: Regulation of cytochrome P450 expression by the aryl hydrocarbon (AH) receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. *Biochem Pharmacol.* 56:599-612 (1998).

Pohjanvirta R, Wong J, Li W, Harper PA, Tuomisto, J, **Okey AB**: Point mutation in an intron sequence causes altered C-terminal structure in the AH receptor of the most TCDD-resistant rat strain. *Mol Pharmacol*. 54: 86-93 (1998).

Okey AB, Harper PA, Grant, DM, Hill RP: Chemical and radiation carcinogenesis. In: Tannock I, Hill R, eds. *The Basic Science of Oncology*. McGraw-Hill, New York, pp. 166-196 (1998).

Okey AB, Harper PA: Chemical carcinogenesis. In: Kalant H, Roschlau WHE, eds. *Principles of Medical Pharmacology*, 6th ed. Oxford University Press, New York, pp. 860-872 (1998).

"P, Q"

Al-Hassan JM, Ali M, Thomson M and **Pace-Asciak CR**: Detection of 8-epi prostaglandin F2a in an extract of epidermal secretion of the catfish from the Arabian Gulf. *Prostagl. Leukot Essential Fatty Acids* 59: 325-328 (1998).

Chiba M, Schwab AJ, Goresky CA, and **Pang KS**: Carrier-mediated entry of 4-methylumbelliferyl sulfate: Characterization by the multiple indicator dilution technique in perfused rat liver. *Hepatology* 27: 134-146 (1998).

Geng W, Schwab AJ, Horie T, Goresky CA, and **Pang KS**: Hepatic uptake of bromosulphophthalein-glutathione in perfused EHBR mutant liver: A multiple indicator dilution

study. *J Pharmacol Exp Ther*. 284: 480-492 (1998).

Pang KS, Wang PJ, Chung AF and Wolkoff AW: The modified dipeptide enalapril, an angiotensin converting enzyme (ACE) inhibitor, is transported by the rat liver organic anion transport protein (oatp1). *Hepatology* 28: 1341-1346 (1998).

Schwab AJ, Geng W and **Pang KS**: Application of the dispersion model for description of the outflow dilution profiles of noneliminated reference indicators in rat liver perfusion studies. *J Pharmacokin Biopharm*. 26: 163-181 (1998).

Sirianni GL and **Pang KS**: Intracellular and not intraluminal esterolysis of enalapril in kidney: Studies with the single pass perfused nonfiltering rat kidney. *Drug Metab Dispos*. 26: 324-331 (1998).

Tirona RG, Schwab AJ, Geng W, and **Pang KS**: Comparison of the dispersion and Goresky models in outflow dilution profiles from multiple indicator rat liver studies. *Drug Metab Dispos.* 26: 465-475 (1998).

Yoshimura T, Schwab AJ, Tao L, Barker F, and **Pang KS**: Hepatic uptake of hippurate: A multiple indicator dilution, perfused rat liver study. *Am J Physiol.* 274 (Gastrointest Liver Physiol 37): G10-G20 (1998).

Goresky CA, Bach GG, Schwab AJ and **Pang KS**: Liver cell entry in vivo and enzymic conversion. In: Bassingthwaigthe J, Goresky CA, Lenihan JN eds. *Whole Organ Approach to Cellular Metabolism: Capillary permeation, Cellular Transport and Reaction Kinetics* Springer-Verlag, Berlin, pp. 297-324 (1998).

Pang KS, Geng W, Schwab AJ and Goresky CA: Probing the structure and function of the liver with the multiple indicator dilution technique. *Op cit.* Pp. 325-368 (1998).

Pang KS and Tirona RG: Significance of liver models in pharmacokinetics. In: Gramatt=E9 T, Weiss MW eds. *Clinical Pharmacology 15, Aspekte der intestinalen Absorption und der Modellentwicklung in Pharmakokinetik und Pharmackodynamik*, W. Zuckschwerdt Verlag, Munchen, pp. 19-44 (1998).

Jahromi BS, Zhang L, **Pennefather P**, and Carlen PL: Ca^{2+} -dependent slow afterhyperpolarization and associated Ca^{2+} transients are differentially affected by BAPTA in rat CA1 neurones. *Neuroscience* 88: 719-726 (1998).

Pennefather PS, Zhou W, DeCoursey TE: Idiosyncratic gating of HERG-like K⁺ channels in microglia. *J General Physiology* 111: 795-805 (1998).

Zhou W, Cayabyab FS, **Pennefather PS**, Schlichter LC, DeCoursey TE: HERG-like K⁺ channels in microglia. *J General Physiology* 111: 781-94 (1998).

Andreou ER, **Prokipcak RD**: Analysis of human CYP7A1 mRNA decay in HepG2 cells by reverse transcription-polymerase chain reaction. *Arch Biochem Biophys.* 357:137-146 (1998).

"R"

Beaumont PO, Moore MJ, Ahmad K, Payne MM, Lee C, **Riddick DS**: Role of glutathione S-transferases in the resistance of human colon cancer cell lines to doxorubicin. *Cancer Res.* 58: 947-955 (1998).

Riddick DS: Drug biotransformation. In: Kalant H, Roschlau WHE, eds. *Principles of Medical Pharmacology*, 6th ed. Oxford University Press, New York, pp 38-54 (1998).

Lawler JF Jr, Yin M, Diehl AM, **Roberts EA**, Chatterjee S: Tumor necrosis factor- α stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. *J Biol Chem.* 273: 5053-5059 (1998).

Marotta PJ, **Roberts EA:** Pemoline hepatotoxicity in children. *J Pediatr.* 132: 894-897 (1998).

Roberts EA, King SM, Fearon M, McGee N: Hepatitis C in children after transfusion: assessment by look-back studies. *Acta-Gastroenterologica-Belgica* 61: 195-197 (1998).

Roberts EA, Cox DW: Wilson Disease. *Baillie's Clinical Gastroenterology* 12: 237-256 (1998).

Selden C, **Roberts EA**, Stamp G, Parker K, Winlove P, Ryder T, Platt H, Hodgson H: Comparison of three solid phase supports for promoting three-dimensional growth and function of human liver cell lines. *Artif Organs* 22: 308-319 (1998).

Sokal EM, Conjeevaram HS, **Roberts EA**, Alvarez F, Bern EM, Goyens P, Rosenthal P, Lachaux A, Shelton M, Sarles J, Hoofnagle J: Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. *Gastroenterology* 114: 988-995 (1998).

Cox DW, **Roberts EA:** Wilson disease. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. *Gastrointestinal Disease*, W. B. Saunders, Philadelphia, pp. 1104-1112 (1998).

Kalant H, **Roberts EA:** Drugs, alcohol and the liver. In: Kalant H and Roschlau WHE, eds. *Principles of Medical Pharmacology*, Oxford University Press, New York, pp. 572-585 (1998).

Roberts EA: Drugs used in the treatment of intestinal motility disorders and inflammatory disease. *Op cit.* pp. 561-571 (1998).

Roberts EA: Pharmacotherapy of acid-peptic disease. *Op cit.* pp. 551-560 (1998).

Roberts EA: Drug hepatitis in children. In: Altschuler S and Liacouros C, eds. *Pediatric Gastroenterology*, W. B. Saunders, Philadelphia, pp.349-355 (1998).

Roberts EA: Primary sclerosing cholangitis in children. In: Krawitt E, Nishioka M, Wiesner RH, eds *Autoimmune Liver Diseases*, Elsevier, New York, pp. 433-447 (1998).

"S"

Colantonio CM, Kwan W, Czerwinski W, Mitchell J, **Schimmer BP**: Altered G protein activity in a desensitization-resistant mutant of the Y1 adrenocortical tumor cell line. *Endocrinology* 139: 626-633 (1998).

Parissenti AM, Kirwan AF, Kim SA, Colantonio CM, **Schimmer BP**: Inhibitory properties of the regulatory domains of human protein kinase C_{alpha} and mouse protein kinase C_{epsilon}. *J Biol Chem*. 273: 8940-8945 (1998).

Parker KL, **Schimmer BP**: Ahch and the feminine mystique. *Nature Genet*. 20: 318-319 (1998).

Qiu R, Frigeri C, **Schimmer BP**: A role for guanyl nucleotide-binding regulatory protein beta and gamma-subunits in the expression of the adrenocorticotropin receptor. *Mol Endocrinol*. 12: 1879-1887 (1998).

George SR, Lee SP, Varghese G, Zeman PR, **Seeman P**, Ng GYK, O'Dowd BF: A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization. *J Biol Chem*. 273: 30244-30248 (1998).

Liu ISC, Kusumi I, Ulpian C, Tallerico T, **Seeman P**: A serotonin-4-receptor-like pseudogene in humans. *Mol Brain Res*. 53: 98-103 (1998).

Nam D, Qian IHP, Kusumi I, Ulpian C, Tallerico T, Liu ISC, **Seeman P**: The human serotonin-7 receptor pseudogene: variation and chromosome location. *J Psychiat Neurosci*. 23: 214-216 (1998).

Qian IHP, Kusumi I, Ulpian C, Tallerico T, Nam D, Liu I, Seeman MV, **Seeman P**: A human serotonin-7 receptor pseudogene. *Mol Brain Res*. 53: 339-343 (1998).

Seeman P: Comment on "Position emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients" by AL Nordstrom, S Nyberg, H Olsson, L Farde. *Arch Gen Psychiat*. 55: 284-284 (1998).

Seeman P, Tallerico T: Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. *Mol Psychiat*. 3: 123-134 (1998).

Seeman P, Madras BK: Anti-hyperactivity medication: methylphenidate and amphetamine. *Mol Psychiat*. 3: 386-396 (1998).

Zawarynski P, Tallerico T, **Seeman P**, Lee SP, O'Dowd BF, George SR: Dopamine D2 receptor dimers in human and rat brain. *FEBS Letts.* 441: 383-386 (1998).

Buczek Y, Le AD, **Sellers EM**, Tomkins DM: Effect of pentylenetetrazole on ethanol intake, ethanol kinetics, and social behaviour in male Wistar rats. *Alcoholism Clin Exp Res.* 22: 428-436 (1998).

Busto UE, Sproule BA, Knight K, Romach MK, **Sellers EM**: Severe dependence on oral opioids. *Can J Clin Pharmacol.* 15: 23-28 (1998).

Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, **Sellers EM**, Tyndale RF: Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. *Pharmacogenetics* 8: 325-333 (1998).

Gaedigk A, Tyndale RF, Jurima-Romet M, **Sellers EM**, Grant DM, Leeder JS: NAD(P)H:quinone oxidoreductase (NQO1): Polymorphisms and allele frequencies in Caucasian, Chinese, and Canadian Native Indian and Inuit populations. *Pharmacogenetics* 8: 305-313 (1998).

Nowak MP, **Sellers EM**, Tyndale RF: Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. *Clin Pharmacol Ther.* 64: 378-383 (1998).

Ozdemir V, Naranjo CA, Herrmann N, Shulman RW, **Sellers EM**, Reed K, Kalow W: The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. *J Clin Psychopharmacology* 18: 55-61 (1998).

Pianezza ML, **Sellers EM**, Tyndale RF: Nicotine metabolism defect reduces smoking. *Nature* 393: 750 (1998).

Romach MK, Kaplan HL, Busto UE, Somer G, **Sellers EM**: A controlled trial of ondansetron, a 5-HT₃ antagonist, in benzodiazepine discontinuation. *J Clin Psychopharmacol.* 18: 21-131 (1998).

Sellers EM: Pharmacogenetics and ethnol-racial differences in smoking (editorial). *JAMA* 280: 179-180 (1998).

Tyndale RF, Droll KP, **Sellers EM**: Relevance of deficient CYP2D6 in opiate dependence. *Pharmacogenetics* 8: 567-568 (1998).

Zawertailo LA, Gomez-Mancilla B, Kaplan HL, Tyndale RF, **Sellers EM**: Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: A pilot study. *J Clin Psychopharmacol.* 18: 332-337 (1998).

Romach MK, **Sellers EM**: Alcohol dependence: Women, biology, and pharmacotherapy. In: McCance-Katz EF, Kosten TR eds. *New Treatments for Chemical Addictions*. American Psychiatric Press, Inc., Washington, DC, pp. 35-73 (1998).

Sellers EM, Romach MK: Drug interactions. In: Kalant H, Roschlau WHE eds. *Principles of Medical Pharmacology*, 6th ed. Oxford University Press, New York, pp. 801-810 (1998).

Sellers EM, Khanna JM, Romach MK: Anxiolytics and hypnotics. *Op cit.* pp. 317-330 (1998).

Lazarus AH, Freedman J, **Semple JW**: Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP: mechanism of action). *Transfusion Sci.* 19: 289-294 (1998).

Semple JW, Lazarus AH, Freedman JF: The cellular immunology associated with autoimmune thrombocytopenic purpura.e pathogenesis of autoimmune thrombocytopenic purpura. *Transfusion Sci.* 19: 245-251 (1998).

Semple JW: The immunobiology of T helper cells and antigen presenting cells in autoimmune thrombocytopenic purpura. *Acta Paediatrica.* 87 (suppl 424): 41-45 (1998).

Gupta AK, del Rosso JQ, Lynde CW, Brown GH, **Shear NH**: Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. *Clin Exp Dermatol.* 23: 64-7 (1998).

Gupta AK, **Shear NH**: Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. *Br J Dermatol.* 138: 529-532 (1998).

Gupta AK, Summerbell R, Einarson TE, **Shear NH**: An overview of topical antifungal therapy in dermatomycoses. *Drugs* 55: 645-74 (1998).

Gupta AK, Soori GS, Del Rosso JQ, Bartos PB, **Shear NH**: Severe neutropenia associated with oral terbinafine therapy. *J Am Acad Dermatol.* 765-7 (1998).

Gupta AK, Koren G, **Shear NH**: A double-blind, randomized, placebo-controlled trial of eutectic lidocaine/prilocaine cream 5% (EMLA) for analgesia prior to cryotherapy of warts in children and adults. *Ped Dermatol.* 15: 146-50 (1998).

Gupta AK, **Shear NH**: A questionnaire study on the management of onychomycosis: A Canadian perspective. *Int J Dermatol.* 37: 457-46 (1998)..

Knowles S, Gupta AK, **Shear NH**: The spectrum of cutaneous reactions associated with diltiazem: Three cases and a review of the literature. *J Am Acad Dermatol.* 38: 201-6 (1998).

Liu B, Anderson G, Mittmann N, To T, Axcell T, **Shear NH**: Use of selective serotonin reuptake inhibitors or tricyclic antidepressants and risk of hip fracture in elderly people. *Lancet* 351: 1303-1307. (1998).

Mittmann N, Herrmann N, Shulman K, Silver IL, **Shear NH**, Naranjo CA: Comparison of the global assessment of functioning scale and the Montgomery Asberg depression rating scale in elderly depressed patients. *Int J Geriatr Psychiatr.*13: 568-74 (1998).

Neuman MG, **Shear NH**, Bellentani S, Tiribelli C: The role of cytokines in ethanol-induced cytotoxicity in vitro in HepG2 cells. *Gastroenterology* 115: 157-166 (1998).

Nulman I, Berkovitch M, Klein J, Pastuszak A, Lester RS, **Shear NH**, Koren G. Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety. *J Clin Pharmacol.* 38: 926-30 (1998).

Phillips E, Knowles S, Weber E, **Shear NH**: Skin reactions associated with bisphosphonates: a report of 3 cases and an approach to management. *J Allerg Clin Immunol.* 102: 697-8 (1998).

Schlienger RG, Shapiro LE, **Shear NH**: Lamotrigine-induced severe cutaneous adverse reactions. *Epilepsia* 39: S22-S26 (1998).

Schlienger RG, Oh PI, Knowles SR, **Shear NH**: Quantifying the costs of serious adverse reactions to anticonvulsants. *Epilepsia* 39: S27-S32 (1998).

Schlienger RG, **Shear NH**. Anti-epileptic drug hypersensitivity syndrome. *Epilepsia* 39 (S7): S3- S7 (1998).

Schlienger RG, Knowles SR, **Shear NH**: Lamotrigine-associated anticonvulsant hypersensitivity syndrome. *Neurology* 51: 1172-5 (1998).

Shear NH: Antihistamines: Safer than you might think. *J Cut Med Surg.* 3: 23-24 (1998).

Shear NH, Einarson TR, Arikian SR, Doyle JJ, van Assche D: Pharmacoeconomic analysis of topical treatments for tinea infections. *Inter J Dermatol.* 37: 64-71 (1998).

Tran C, Knowles SR, Liu BA, **Shear NH**: Gender differences in adverse drug reactions. *J Clin Pharmacol.* 38: 1003-9 (1998).

"T"

Kalow W, **Tang BK**, Endrenyi L: Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. *Pharmacogenetics* 8: 283-9 (1998).

Li W, Harper PA, **Tang BK**, Okey AB: Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. *Biochem Pharmacol* 56: 599-612 (1998).

Buczek Y, Le AD, Sellers EM, **Tomkins DM**: Effect of pentylenetetrazole on ethanol intake, ethanol kinetics, and social behavior in male Wistar rats. *Alcoholism Clin Exp Res.* 22: 428-36 (1998).

Bronstein JM, Hales TG, **Tyndale RF**, Charles AC: A conditionally immortalized glial cell line that expresses mature myelin proteins and functional GABA_A receptors. *J Neurochem.* 70: 483-491 (1998).

Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM, **Tyndale RF**: Comparison of the three CYP2D6 probe substrates and genotype in Guanaians, Chinese, and Caucasians. *Pharmacogenetics* 8: 325-334 (1998).

Gaedigk A, **Tyndale RF**, Jurima-Romet M, Sellers EM, Grant DM, Leeder JS: NAD(P)H:Quinone oxidoreductase (NQO1): polymorphisms and allele frequencies in Caucasian, Chinese, and Canadian Native Indian and Inuit populations. *Pharmacogenetics* 8: 305-314 (1998).

Nowak MP, Sellers EM, **Tyndale RF**: Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. *Clin Pharmacol Ther.* 64: 378-383 (1998).

Pianezza M, Sellers EM, **Tyndale RF**: Nicotine metabolism defect reduces smoking. *Nature* 393: 750 (1998).

Tyndale RF, Droll K D, Sellers EM: Relevance of deficient CYP2D6 in opiate dependence. *Pharmacogenetics* 8: 567-568 (1998).

Zawertailo LA, Kaplan HL, Busto UA, **Tyndale RF**, Sellers EM: Psychotropic effects of dextromethorphan are altered by the CYP2D6 Polymorphism: A pilot study. *J Clin Psychopharmacol* 18: 332-337 (1998).

"U"

Gardner I, Zahid N, MacCrimmon D, **Utrecht JP**: A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. *Mol. Pharmacol.* 53: 991-998 (1998).

Gardner I, Leeder JS, Zahid N, **Utrecht JP**: A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. *Mol. Pharmacol.* 53: 999-1008 (1998).

Ju C, **Utrecht JP**: Oxidation of a metabolite of indomethacin (desmethyldeschloro-benzoylindomethacin) to reactive intermediates by activated neutrophils, hypochlorous acid and the myeloperoxidase system. *Drug Metab. Dispos.* 26: 676-680 (1998).

"V"

Knapp M, Wong AHC, Schoots O & **Van Tol HHM**: Promoter-independent regulation of cell-specific dopamine receptor expression. *FEBS Lett.* 434: 108-114 (1998).

Oldenhof J, Vickery R, Anafi M, Oak J, Ray A, Schoots O, Pawson T, von Zastrow M & **Van Tol HHM**: SH3 binding domains in the dopamine D4 receptor. *Biochemistry* 37: 15726-15736 (1998).

Seeman P, Corbett R & **Van Tol HHM**: Dopamine D4 receptors may alleviate antipsychotic-induced Parkinsonism. *Adv in Pharmacol.* 42: 478-482 (1998).

Van Tol HHM: Structural and functional characteristics of the dopamine D4 receptor. *Adv in Pharmacol.* 42: 486-490 (1998).

Wilson J, Sanyal SS & **Van Tol HHM**: Dopamine D2 and D4 receptor ligands: relation to antipsychotic action. *Eur J Pharmacol.* 351: 273-286 (1998).

"W, X, Y, Z"

Kofman O, Li PP, **Warsh JJ**: Lithium, but not carbamazepine, potentiates hyperactivity induced by intra-accumbens cholera toxin. *Pharmacol Biochem Behavior* 59: 191-200 (1998).

Parman T, Chen G, **Wells PG**: Free radical intermediates of phenytoin and related teratogens: prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry and photochemical product analysis. *J Biol Chem.* 273: 25079-25088 (1998).

Winn LM, Kim PM, **Wells PG**: Investigation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3 pyridyl)-1-butanone (NNK) for in vivo and in vitro murine embryopathy and embryonic ras mutations. *J Pharmacol Exp Ther.* 287: 1128-1135 (1998).
